Zoetis Inc. (0M3Q.L)
USD 148.98
(1.16%)
USD 148.98
(1.16%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.76 Billion USD | 2.48% |
| 2022 | 2.69 Billion USD | 1.05% |
| 2021 | 2.67 Billion USD | 13.67% |
| 2020 | 2.34 Billion USD | 4.4% |
| 2019 | 2.25 Billion USD | 10.67% |
| 2018 | 2.03 Billion USD | 12.51% |
| 2017 | 1.8 Billion USD | -0.99% |
| 2016 | 1.82 Billion USD | -6.75% |
| 2015 | 1.95 Billion USD | -6.77% |
| 2014 | 2.09 Billion USD | 1.3% |
| 2013 | 2.07 Billion USD | 6.64% |
| 2012 | 1.94 Billion USD | -0.31% |
| 2011 | 1.94 Billion USD | 5.29% |
| 2010 | 1.85 Billion USD | 26.18% |
| 2009 | 1.46 Billion USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 752 Million USD | 6.06% |
| 2024 Q1 | 709 Million USD | -4.06% |
| 2024 Q3 | 732 Million USD | -2.66% |
| 2023 Q2 | 739 Million USD | 8.04% |
| 2023 FY | 2.76 Billion USD | 2.48% |
| 2023 Q1 | 684 Million USD | -1.87% |
| 2023 Q3 | 715 Million USD | -3.25% |
| 2023 Q4 | 739 Million USD | 3.36% |
| 2022 Q1 | 628 Million USD | -18.55% |
| 2022 FY | 2.69 Billion USD | 1.05% |
| 2022 Q4 | 697 Million USD | 3.72% |
| 2022 Q3 | 672 Million USD | -4.14% |
| 2022 Q2 | 701 Million USD | 11.62% |
| 2021 Q4 | 771 Million USD | 14.05% |
| 2021 Q2 | 656 Million USD | 15.7% |
| 2021 FY | 2.67 Billion USD | 13.67% |
| 2021 Q3 | 676 Million USD | 3.05% |
| 2021 Q1 | 567 Million USD | -18.18% |
| 2020 Q4 | 693 Million USD | 20.31% |
| 2020 FY | 2.34 Billion USD | 4.4% |
| 2020 Q1 | 536 Million USD | -16.77% |
| 2020 Q2 | 544 Million USD | 1.49% |
| 2020 Q3 | 576 Million USD | 5.88% |
| 2019 Q1 | 509 Million USD | -12.84% |
| 2019 Q4 | 644 Million USD | 19.04% |
| 2019 FY | 2.25 Billion USD | 10.67% |
| 2019 Q3 | 541 Million USD | -2.7% |
| 2019 Q2 | 556 Million USD | 9.23% |
| 2018 Q2 | 484 Million USD | 5.68% |
| 2018 Q1 | 458 Million USD | -7.29% |
| 2018 FY | 2.03 Billion USD | 12.51% |
| 2018 Q4 | 584 Million USD | 15.19% |
| 2018 Q3 | 507 Million USD | 4.75% |
| 2017 Q3 | 447 Million USD | 0.45% |
| 2017 Q1 | 421 Million USD | -14.08% |
| 2017 FY | 1.8 Billion USD | -0.99% |
| 2017 Q4 | 494 Million USD | 10.51% |
| 2017 Q2 | 445 Million USD | 5.7% |
| 2016 Q3 | 456 Million USD | 0.66% |
| 2016 FY | 1.82 Billion USD | -6.75% |
| 2016 Q1 | 426 Million USD | -22.55% |
| 2016 Q2 | 453 Million USD | 6.34% |
| 2016 Q4 | 490 Million USD | 7.46% |
| 2015 FY | 1.95 Billion USD | -6.77% |
| 2015 Q4 | 550 Million USD | 14.58% |
| 2015 Q3 | 480 Million USD | 0.42% |
| 2015 Q2 | 478 Million USD | 6.46% |
| 2015 Q1 | 449 Million USD | -29.29% |
| 2014 FY | 2.09 Billion USD | 1.3% |
| 2014 Q4 | 635 Million USD | 26.24% |
| 2014 Q3 | 503 Million USD | 0.0% |
| 2014 Q1 | 458 Million USD | -22.9% |
| 2014 Q2 | 503 Million USD | 9.83% |
| 2013 Q1 | 462 Million USD | -21.69% |
| 2013 Q2 | 509 Million USD | 10.17% |
| 2013 Q3 | 507 Million USD | -0.39% |
| 2013 Q4 | 594 Million USD | 17.16% |
| 2013 FY | 2.07 Billion USD | 6.64% |
| 2012 Q4 | 590 Million USD | 32.58% |
| 2012 Q3 | 445 Million USD | -1.55% |
| 2012 FY | 1.94 Billion USD | -0.31% |
| 2012 Q2 | 452 Million USD | -0.88% |
| 2012 Q1 | 456 Million USD | -19.15% |
| 2011 FY | 1.94 Billion USD | 5.29% |
| 2011 Q1 | 452 Million USD | 0.0% |
| 2011 Q2 | 483 Million USD | 6.86% |
| 2011 Q3 | 450 Million USD | -6.83% |
| 2011 Q4 | 564 Million USD | 25.33% |
| 2010 FY | 1.85 Billion USD | 26.18% |
| 2009 FY | 1.46 Billion USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 73.035% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -576.36% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -902.927% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1840.855% |
| uniQure N.V. | 285.08 Million USD | -869.883% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -546.555% |
| bluebird bio, Inc. | 240.23 Million USD | -1050.971% |
| Imunon, Inc. | 21.03 Million USD | -13047.615% |
| Dynavax Technologies Corporation | 219.14 Million USD | -1161.722% |
| Editas Medicine, Inc. | 247.3 Million USD | -1018.057% |
| Illumina, Inc. | 3.81 Billion USD | 27.485% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -513.092% |
| IQVIA Holdings Inc. | 2.05 Billion USD | -34.681% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -153.812% |
| Myriad Genetics, Inc. | 600.1 Million USD | -360.757% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -73.191% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -103.187% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -422.673% |
| Verastem, Inc. | 92.08 Million USD | -2902.693% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 93.19% |
| Waters Corporation | 943.51 Million USD | -193.052% |
| Biogen Inc. | 5.2 Billion USD | 46.877% |
| Nektar Therapeutics | 190.9 Million USD | -1348.38% |
| Perrigo Company plc | 1.52 Billion USD | -80.896% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -19778.299% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -2191.62% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -6090.252% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -58.337% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -1109.113% |
| Evolus, Inc. | 189.75 Million USD | -1357.111% |
| Adicet Bio, Inc. | 152.03 Million USD | -1718.624% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -22674.071% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 1.787% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -916.929% |
| FibroGen, Inc. | 398.11 Million USD | -594.526% |
| Agilent Technologies, Inc. | 2.11 Billion USD | -30.733% |
| OPKO Health, Inc. | 574.68 Million USD | -381.132% |
| Homology Medicines, Inc. | 9.87 Million USD | -27900.0% |
| Geron Corporation | 70.44 Million USD | -3825.271% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -53.606% |
| Exelixis, Inc. | 1.58 Billion USD | -74.253% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -2642.321% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -4859.108% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -401.3% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -480.443% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -5600.796% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 42.094% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -6962.039% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -254.675% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -650.111% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -823.767% |
| Blueprint Medicines Corporation | 722.86 Million USD | -282.508% |
| Insmed Incorporated | 949.26 Million USD | -191.279% |
| TG Therapeutics, Inc. | 198.47 Million USD | -1293.123% |
| Incyte Corporation | 1.19 Billion USD | -132.256% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -164.847% |